Myogenes Clozapine Test promises to improve outcomes for schizophrenia patients

FHS
October 4, 2024
11:34 am

Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.

Lonza extends contract with unnamed pharma; Rentschler’s new build

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza said it has Sign up

October 25, 2024

Harnessing artificial intelligence for infectious disease prevention

A new research review to be given at a pre-congress day for this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) will

February 28, 2024

Pα+ Psychedelic Bulletin #165: A Closer Look at a Buzzy Oral Ketamine for Depression Study; UN Weighs In on Psychedelics; Another CA Psychedelics Bill Fails – Psychedelic Alpha

In this Issue Phase 2 Study of Oral Ketamine for Depression Lauded by Media and Sponsor, Yet Closer Look Reveals Underwhelming Results UN World Drug

June 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.